Daré Bioscience Disclosed Failure to Satisfy a Continued Listing Rule or Standard
Daré Bioscience (DARE) received a notice from Nasdaq on September 28, 2026, for failing to maintain a $1.00 minimum bid price for 30 consecutive days. The company has until March 29, 2027, to comply, with a possible 180-day extension if criteria are met.
How this was made
The 30-second read
Why it matters
The notice signals a material compliance risk that could depress the stock until the company regains the $1 threshold or takes corrective action.
Market read
The filing is a primary disclosure of a compliance breach that may trigger short‑term selling pressure.
What to watch
Potential for a reverse split or share consolidation to regain compliance.
Background
Listing Rule 5550(a)(2) requires a minimum $1.00 bid price for 30 consecutive days; non‑compliance triggers a notice and possible delisting.
Ticker impact
Nasdaq notified Daré Bioscience that its share price fell below $1 for 30 days, triggering a compliance notice.
likely pressure as investors price in compliance risk
Failure to meet bid price rule often leads to share sell‑offs and possible suspension.
Market effects
May affect other low‑price biotech stocks facing similar listing standards.
Limited to U.S. Nasdaq‑listed microcaps.
Low
Counterpoint
If the company raises capital quickly, the compliance issue could be resolved without major price impact.
Key entities
- Regulatory BodyNasdaq
Issuer of the compliance notice.
- CompanyDaré Bioscience
Subject of the listing compliance notice.
